The HOXC10/NOD1/ERK axis drives osteolytic bone metastasis of pan-KRAS-mutant lung cancer

Abstract

While KRAS mutation is the leading cause of low survival rates in lung cancer bone metastasis patients, effective treatments are still lacking. Here, we identified homeobox C10 (HOXC10) as a lynchpin in pan-KRAS-mutant lung cancer bone metastasis. Through RNA-seq approach and patient tissue studies, we demonstrated that HOXC10 expression was dramatically increased. Genetic depletion of HOXC10 preferentially impeded cell proliferation and migration in vitro. The bioluminescence imaging and micro-CT results demonstrated that inhibition of HOXC10 significantly reduced bone metastasis of KRAS-mutant lung cancer in vivo. Mechanistically, the transcription factor HOXC10 activated NOD1/ERK signaling pathway to reprogram epithelial-mesenchymal transition (EMT) and bone microenvironment by activating the NOD1 promoter. Strikingly, inhibition of HOXC10 in combination with STAT3 inhibitor was effective against KRAS-mutant lung cancer bone metastasis by triggering ferroptosis. Taken together, these findings reveal that HOXC10 effectively alleviates pan-KRAS-mutant lung cancer with bone metastasis in the NOD1/ERK axis-dependent manner, and support further development of an effective combinatorial strategy for this kind of disease.

[graphic not available: see fulltext]

References

[1] Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J. Clin., 2023, 73: 17-48

[2] Jasper K, Stiles B, McDonald F, Palma DA. Practical management of oligometastatic non-small-cell lung cancer. J. Clin. Oncol., 2022, 40: 635-641

[3] Huang X et al. Mutational characteristics of bone metastasis of lung cancer. Ann. Palliat. Med, 2021, 10: 8818-8826

[4] Del Conte, A. et al. Bone metastasis and immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Microenvironment and possible clinical implications. Int. J. Mol. Sci. 23 (2022).

[5] Bittner N et al. Bone metastases and the EGFR and KRAS mutation status in lung adenocarcinoma-the results of three year retrospective analysis. Pathol. Oncol. Res., 2015, 21: 1217-1221

[6] Altorki NK et al. The lung microenvironment: an important regulator of tumour growth and metastasis. Nat. Rev. Cancer, 2019, 19: 9-31

[7] Lohinai Z et al. KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis. Sci. Rep., 2017, 7

[8] Zhao J, Han Y, Li J, Chai R, Bai C. Prognostic value of KRAS/TP53/PIK3CA in non-small cell lung cancer. Oncol. Lett., 2019, 17: 3233-3240

[9] Punekar SR, Velcheti V, Neel BG, Wong KK. The current state of the art and future trends in RAS-targeted cancer therapies. Nat. Rev. Clin. Oncol., 2022, 19: 637-655

[10] Zhu C et al. Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Mol. Cancer, 2022, 21

[11] Awad MM et al. Acquired resistance to KRAS(G12C) inhibition in cancer. N. Engl. J. Med., 2021, 384: 2382-2393

[12] Multiple Mechanisms Underlie the Acquired Resistance to KRAS G12C Inhibition. Cancer Discov. 12, OF7 (2022).

[13] Fang J, Wang J, Yu L, Xu W. Role of HOXC10 in cancer. Front. Oncol., 2021, 11

[14] Guan Y et al. Overexpression of HOXC10 promotes glioblastoma cell progression to a poor prognosis via the PI3K/AKT signalling pathway. J. Drug Target, 2019, 27: 60-66

[15] Sadik H et al. HOXC10 expression supports the development of chemotherapy resistance by fine tuning DNA repair in breast cancer cells. Cancer Res., 2016, 76: 4443-4456

[16] Guo C, Hou J, Ao S, Deng X, Lyu G. HOXC10 up-regulation promotes gastric cancer cell proliferation and metastasis through MAPK pathway. Chin. J. Cancer Res., 2017, 29: 572-580

[17] Kim J et al. HOXC10 overexpression promotes cell proliferation and migration in gastric cancer. Oncol. Rep., 2019, 42: 202-212

[18] Miao Y et al. HOXC10 promotes growth and migration of melanoma by regulating Slug to activate the YAP/TAZ signaling pathway. Discov. Oncol., 2021, 12: 12

[19] Xie, Y. et al. Transcription factor HOXC10 activates the expression of MTFR2 to regulate the proliferation, invasion and migration of colorectal cancer cells. Mol. Med. Rep. 24 (2021).

[20] Tang XL et al. HOXC10 promotes the metastasis of human lung adenocarcinoma and indicates poor survival outcome. Front. Physiol., 2017, 8: 557

[21] Li M, Alsager JS, Wang Z, Cheng L, Shan B. Epigenetic upregulation of HOXC10 in non-small lung cancer cells. Aging (Albany NY), 2020, 12: 16921-16935

[22] Popper HH. Progression and metastasis of lung cancer. Cancer Metastasis Rev., 2016, 35: 75-91

[23] Mao L et al. Proteomic analysis of lung cancer cells reveals a critical role of BCAT1 in cancer cell metastasis. Theranostics, 2021, 11: 9705-9720

[24] Zhu, L. et al. Osteoclast-mediated bone resorption is controlled by a compensatory network of secreted and membrane-tethered metalloproteinases. Sci. Transl. Med. 12 (2020).

[25] Dang Y et al. Interleukin 1beta-mediated HOXC10 overexpression promotes hepatocellular carcinoma metastasis by upregulating PDPK1 and VASP. Theranostics, 2020, 10: 3833-3848

[26] Chen YY, Ge JY, Zhu SY, Shao ZM, Yu KD. Copy number amplification of ENSA promotes the progression of triple-negative breast cancer via cholesterol biosynthesis. Nat. Commun., 2022, 13

[27] Velloso, F. J., Trombetta-Lima, M., Anschau, V., Sogayar, M. C. & Correa, R. G. NOD-like receptors: major players (and targets) in the interface between innate immunity and cancer. Biosci. Rep. 39 (2019).

[28] Castano-Rodriguez N, Kaakoush NO, Goh KL, Fock KM, Mitchell HM. The NOD-like receptor signalling pathway in Helicobacter pylori infection and related gastric cancer: a case-control study and gene expression analyses. PLoS One, 2015, 10: e0117870

[29] Hayakawa K et al. NLR Nod1 signaling promotes survival of BCR-engaged mature B cells through up-regulated Nod1 as a positive outcome. J. Exp. Med., 2017, 214: 3067-3083

[30] Huhn S et al. Coding variants in NOD-like receptors: an association study on risk and survival of colorectal cancer. PLoS One, 2018, 13: e0199350

[31] Esposito M et al. Bone vascular niche E-selectin induces mesenchymal-epithelial transition and Wnt activation in cancer cells to promote bone metastasis. Nat. Cell Biol., 2019, 21: 627-639

[32] Jing B et al. IL6/STAT3 signaling orchestrates premetastatic niche formation and immunosuppressive traits in lung. Cancer Res., 2020, 80: 784-797

[33] Siersbaek R et al. IL6/STAT3 signaling hijacks estrogen receptor alpha enhancers to drive breast cancer metastasis. Cancer Cell, 2020, 38: 412-423.e419

[34] Liu Z, Ma L, Sun Y, Yu W, Wang X. Targeting STAT3 signaling overcomes gefitinib resistance in non-small cell lung cancer. Cell Death Dis., 2021, 12

[35] Zheng Q et al. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance. Theranostics, 2021, 11: 824-840

[36] Lee HJ et al. A novel C-terminal heat shock protein 90 inhibitor that overcomes STAT3-Wnt-beta-catenin signaling-mediated drug resistance and adverse effects. Theranostics, 2022, 12: 105-125

[37] Redell MS, Ruiz MJ, Alonzo TA, Gerbing RB, Tweardy DJ. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood, 2011, 117: 5701-5709

[38] Verma, N. et al. Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis. Sci. Adv. 6 (2020).

[39] Yan HF et al. Ferroptosis: mechanisms and links with diseases. Signal Transduct. Target Ther., 2021, 6: 49

[40] Stockwell BR et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell, 2017, 171: 273-285

[41] Bendell JC et al. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. Br. J. Cancer, 2017, 116: 575-583

[42] Skoulidis F et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N. Engl. J. Med., 2021, 384: 2371-2381

[43] Pathiraja TN et al. Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Sci. Transl. Med., 2014, 6: 229ra241

[44] Zhai Y et al. Gene expression analysis of preinvasive and invasive cervical squamous cell carcinomas identifies HOXC10 as a key mediator of invasion. Cancer Res, 2007, 67: 10163-10172

[45] Peng Y et al. HOXC10 promotes tumour metastasis by regulating the EMT-related gene Slug in ovarian cancer. Aging (Albany NY), 2020, 12: 19375-19398

[46] Dai BW et al. HOXC10 promotes migration and invasion via the WNT-EMT signaling pathway in oral squamous cell carcinoma. J. Cancer, 2019, 10: 4540-4551

[47] Ma M et al. HOXC10 promotes proliferation and attenuates lipid accumulation of sheep bone marrow mesenchymal stem cells. Mol. Cell Probes, 2020, 49

[48] Suo D et al. HOXC10 upregulation confers resistance to chemoradiotherapy in ESCC tumor cells and predicts poor prognosis. Oncogene, 2020, 39: 5441-5454

[49] Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct. Target Ther., 2021, 6: 386

[50] Lamoureux F et al. Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle. Nat. Commun., 2014, 5

[51] Guerra SL et al. A deregulated HOX gene axis confers an epigenetic vulnerability in KRAS-mutant lung cancers. Cancer Cell, 2020, 37: 705-719.e706

[52] Yao S et al. HOXC10 promotes gastric cancer cell invasion and migration via regulation of the NF-kappaB pathway. Biochem. Biophys. Res. Commun., 2018, 501: 628-635

[53] Wei X et al. Extracellular vesicles from colorectal cancer cells promote metastasis via the NOD1 signalling pathway. J. Extracell. Vesicles, 2022, 11

[54] D’Amico S et al. STAT3 is a master regulator of epithelial identity and KRAS-driven tumorigenesis. Genes Dev., 2018, 32: 1175-1187

[55] Grabner B et al. Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. Nat. Commun., 2015, 6

[56] Ouyang S et al. Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer. Redox Biol., 2022, 52

[57] Nagathihalli NS et al. Inverse correlation of STAT3 and MEK signaling mediates resistance to RAS pathway inhibition in pancreatic cancer. Cancer Res, 2018, 78: 6235-6246

[58] Hu K et al. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma. J. Clin. Invest., 2020, 130: 1752-1766

[59] Li, K. et al. BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer. J. Clin. Invest. 132 (2022).

[60] Zhu Y, Qiu P, Ji Y. TCGA-assembler: open-source software for retrieving and processing TCGA data. Nat. Methods, 2014, 11: 599-600

[61] Romero-Moreno R et al. The CXCL5/CXCR2 axis is sufficient to promote breast cancer colonization during bone metastasis. Nat. Commun., 2019, 10

[62] Li C et al. Integrated Omics of Metastatic Colorectal Cancer. Cancer Cell, 2020, 38: 734-747.e739

Funding

National Natural Science Foundation of China (National Science Foundation of China)(82022051)